Loading...

RGNX REGENXBIO INC Legal Disputes 8-K Filing

RGNX

RGNX

REGENXBIO INC

(RGNX)

2026 8-K

Settlement Agreement

Financial Results Announced

FDA Response Letter

FDA Holds Trials

Financial Results Report

FDA Date Extension

Debt-Equity Swaps

Financial Statements

Financial Results

Collaboration Agreement

Collaboration Agreement

Financial Results

Management Grant of Restric...

Earnings Reports

Management Change

Annual Meeting Voting Results

Earnings Reports

Underwriting Agreement

Financial Results Press Rel...

Earnings Reports

Equity Offering

Earnings Reports

Annual Meeting Voting Results

Earnings Reports

Financial Results Press Rel...

Management Changes

External Links:

On March 18, 2026, REGENXBIO Inc. agreed to pay $10 million to GlaxoSmithKline to settle a dispute regarding underpaid sublicense fees. This agreement resolves past and certain future claims related to their License Agreement initiated in 2009.

AI Assistant

REGENXBIO INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.